Zura Bio | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.21.

EBIT: As of FY2025 Q3, the actual value is USD -21.05 M.

Cash Position

• As of September 30, 2025, Zura Bio Limited had cash and cash equivalents of $139.0 million, which is expected to fund planned operations through 2027.

Research and Development (R&D) Expenses

• R&D expenses were $11.9 million for the third quarter of 2025, compared to $6.0 million for the same period in 2024, primarily reflecting continued advancement of the tibulizumab Phase 2 clinical trials.

General and Administrative (G&A) Expenses

• G&A expenses were $7.6 million for the third quarter of 2025, compared to $13.3 million for the same period in 2024, driven mainly by a one-time non-cash expense in share-based compensation in the third quarter of 2024.

Net Loss

• Net loss for the third quarter of 2025 was $20.0 million, or $0.21 per share, compared to $22.9 million, or $0.26 per share, for the same period in 2024.

Outlook / Guidance

• Zura Bio Limited expects its existing cash and cash equivalents to be sufficient to support operations as currently planned through 2027. Topline data for the TibuSHIELD (HS) Phase 2 clinical trial is expected in the third quarter of 2026, and for the TibuSURE (SSc) Phase 2 clinical trial in the fourth quarter of 2026.